Abstract

**Background:** Standard radiotherapy is the treatment of first choice in patients with symptomatic spinal metastases, but is only moderately effective. Stereotactic body radiation therapy is increasingly used to treat spinal metastases, without randomized evidence of superiority over standard radiotherapy. The VERTICAL study aims to quantify the effect of stereotactic radiation therapy in patients with metastatic spinal disease.

**Methods/design:** This study follows the 'cohort multiple Randomized Controlled Trial' design. The VERTICAL study is conducted within the PRESENT cohort. In PRESENT, all patients with bone metastases referred for radiation therapy are enrolled. For each patient, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. In addition, patients give informed consent to be offered experimental interventions. Within PRESENT, 110 patients are identified as a sub cohort of eligible patients (i.e. patients with unirradiated painful, mechanically stable spinal metastases who are able to undergo stereotactic radiation therapy). After a protocol amendment, also patients with non-spinal bony metastases are eligible. From the sub cohort, a random selection of patients is offered stereotactic radiation therapy ($n = 55$), which patients may accept or refuse. Only patients accepting stereotactic radiation therapy sign informed consent for the VERTICAL trial. Non-selected patients ($n = 55$) receive standard radiotherapy, and are not aware of them serving as controls. Primary endpoint is pain response after three months. Data will be analyzed by intention to treat, complemented by instrumental variable analysis in case of substantial refusal of the stereotactic radiation therapy in the intervention arm.

(Continued on next page)
Background
Bone metastases are a frequent distant manifestation of cancer, with the spinal column being the most common site [1]. Spinal metastases can induce cancer-related pain, mechanical instability, and neural compression, thereby causing morbidity and impacting on quality of life (QOL). Treatment is aimed at pain relief and prevention of neurological deficits. The treatment for most patients with symptomatic spinal metastases is standard external beam radiotherapy [2], which is moderately effective: around 60% of patients who undergo external beam radiotherapy experience pain relief [3]. Furthermore, pain relief is often incomplete with complete pain response rates ranging from 0 and 23% [3] and one in five patients needs re-irradiation [4]. Escalating the dose to the metastatic site might improve the pain response and prolong the duration of pain relief [5]. Dose escalation to spinal tumors using standard radiotherapy is complicated by the low tolerance of the spinal cord to radiation. Stereotactic body radiotherapy (SBRT) is able to deliver precise high-dose radiation to spinal metastases in single or multiple fractions, while sparing surrounding healthy tissues. Phase I and II studies have suggested that, for selected groups of patients, SBRT for spinal metastases may be accurate, safe, and effective [5, 6], with complete pain response in 54% of patients six months after SBRT [7]. Other authors even reported overall pain response rates around 90% [8–10]. To date however, no randomized controlled studies have been performed so equipoise still exist on the effectiveness of SBRT in comparison to standard radiotherapy. Therefore, we designed a pragmatic randomized controlled trial to compare conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases (VERTICAL) following the CONSORT statement [11].

Methods/design
Study design
This study is conducted within the Prospective Evaluation of Interventional StudiEs on boNe meTastases (PRESENT) cohort [12]. All patients with bone metastases referred to the departments or radiation oncology or orthopedic surgery of the University Medical Center Utrecht are asked to participate in this prospective, observational cohort. Baseline and follow-up data are collected from clinical files, and patient-reported outcomes (PROMs, i.e. a pain inventory and QOL questionnaires) are collected at fixed time intervals. This study follows the cohort multiple randomized controlled trial (cmRCT) design as described by Relton and colleagues [13].

Patient recruitment
At enrollment, patients give informed consent for collection of clinical and survival data, and can opt-in to provide PROMs. In addition, in a separate question, we ask patients for their broad consent for future randomization in trials that will investigate the effectiveness of experimental treatments [14]. Patients within the PRESENT cohort who meet the VERTICAL inclusion criteria (Table 1) are identified as a sub cohort of eligible patients. Eligible patients are PROMs-providing participants of the PRESENT cohort, have untreated symptomatic spinal metastases, and have given consent for broad randomization to experimental interventions. Patients are excluded if they are not able to undergo SBRT, have severe or progressive neurological deficits, received previous radiotherapy or surgery to the index site(s), or have a life expectancy less than three months. After a protocol amendment on September 23, 2015 to adjust to developments in clinical practice, also patients with non-spinal bony metastases are eligible.

Random selection
Eligible patients are randomly selected from the sub cohort on a 1:1 basis with varying block sizes (n = six or eight) using an in-house randomization computer program. The radiation oncologist will offer the experimental intervention (i.e. SBRT) to the randomly selected patients. If they accept the treatment offer, they will sign informed consent for participation in the VERTICAL study. Patients who refuse the SBRT will receive care as usual (i.e. standard radiotherapy). According to the cmRCT design, patients in the sub cohort who are not randomly selected will not be informed about the experimental intervention,
nor will they be informed about their participation in the control arm of the VERTICAL study. Outcomes in randomly selected patients are compared with the outcomes in eligible patients not randomly selected who received standard radiotherapy (Fig. 1).

Standard radiotherapy

Standard radiotherapy for symptomatic bony metastases consists of single fraction external beam radiotherapy of 8 Gray (Gy). The radiation oncologist might however choose a multi-fraction regime of 30 Gy in 10 fractions if the patient has a favorable primary tumor (i.e. breast or prostate cancer), a Karnofsky performance score (KPS) of 80–100%, and absence of visceral or brain metastases. The radiation dose distribution usually consists of a single field in posteroanterior direction with the normalization point (100% isodoseline) at 6 cm for a 6 MV photon beam and at 6 or 7 cm for a 10 MV photon beam. The vertebral
body should at least receive 80% of the prescribed dose. If necessary, a field in anteroposterior direction is added to the posteroanterior field. Metastases in the cervical spine are usually treated with two lateral opposing fields. The leaves of the multileaf collimator are used to adjust the shape of the treatment field. Prior to treatment, cone beam computed tomography (CBCT) scan images are obtained to verify that the position of the patient is correct with regard to the planning computed tomography (CT). Currently, our department is working on the clinical implementation of auto-planning for single fraction treatment of patients with bone metastases. Automatic treatment plans will then be delivered to the spinal metastases using intensity-modulated radiation therapy (IMRT) technique.

**Stereotactic body radiotherapy**

Patients in the experimental arm undergoing SBRT are immobilized with an S-frame thermoplastic mask in case of skull or cervical spine tumors extending to the upper thoracic (T3) vertebral body. In case of lower thoracic and lumbar lesions, and rib and pelvic lesions, they are immobilized using a vacuum mattress (BlueBAG™, Elekta, Stockholm, Sweden). Magnetic resonance imaging (MRI) is used to delineate the gross tumor volume (GTV), clinical target volume (CTV), and the organs at risk (OAR). We use MRI guidance to deliver stereotactic radiotherapy to the visible metastasis (i.e. GTV) exclusively. With the aid of T1 weighted, T2 weighted, and diffusion weighted imaging (DWI) sequences, it is possible to delineate the GTV accurately [15, 16]. Adjacent normal appearing bone may harbor subclinical disease and could potentially serve as a source for a local recurrence [17]. Therefore, the bony compartment containing the GTV (i.e. the CTV, which consists of the entire vertebral body, pedicle, transverse process, lamina, or spinous process) is prescribed 8 Gy in order to treat subclinical disease whereas the metastasis receives 18 Gy (Fig. 2). This simultaneous integrated boost approach has the potential advantage of lowering the risk of vertebral compression fractures by sparing the unaffected, healthy bone tissue surrounding the metastasis while also treating subclinical disease. When necessary, an equivalent dose may be given using another fractionation schedule: 30 Gy in three fractions to the visible metastasis with 15 Gy in three fractions to the bony compartment or 35 Gy in five fractions with 20 Gy in five fractions to the bony compartment. Possible reasons to fractionate the dose might be proximity of visible metastasis to the spinal cord or more than two consecutive spine segments involved. Treatment planning is performed on pre-treatment CT and MRI scans that are co-registered to yield information on all relevant structures for assessing dose distribution. Volumetric modulated arc therapy (VMAT) treatment plans are generated for SBRT patients. Dose constraints are set for the OAR based on institution specific guidelines. These constraints, and particularly the constraint of the spinal cord, are of primary concern. If necessary, dose deliverance to the GTV will be limited in order to meet these constraints [18]. For all patients, an online CBCT scan is acquired with the patient in treatment position on the treatment couch just before start of the irradiation. The CBCT scan yields the exact position of the bony anatomy and is registered to the pre-treatment CT and MRI data. The alignment of the patient, or more specifically the affected vertebra bodies, on the CBCT scan is compared with the pre-treatment CT and MRI scans. After possible correction a second CBCT is performed between the two VMAT arcs. A third CBCT is taken post-treatment to document stability of the target during treatment.

**Primary endpoint**

Primary endpoint of this study is complete or partial pain response at three months. Pain response is defined according to the International Bone Metastases Consensus Endpoints for Clinical Trials (Table 2) [19]. A pain score of zero with no concomitant increase in analgesic intake compared to baseline is defined as complete response. Partial response is pain reduction of at least two points on a scale of 0–10 without increase in analgesic intake and/or analgesic reduction of at least 25% from baseline without an increase in pain. Pain progression is defined as an increase in pain score of at least two points above baseline with stable analgesic use and/or as

![Fig. 2](image-url)

*Fig. 2* Standard radiotherapy and stereotactic body radiotherapy. Comparison of a conventional radiation dose distribution using standard radiotherapy (left) with a spinal stereotactic radiotherapy simultaneous integrated boost distribution (right) in a patient with a T4 vertebral body metastasis from breast cancer.
Patients fill out these QOL questionnaires and the BPI of the EORTC QLQ-C30 specially developed for use in specific module, the EORTC QLQ-BM22 [24]. The general questionnaire [23] and the bone metastases-specific module, the EORTC QLQ-C15-PAL, are validated for use in advanced cancer patients to assess pain and functional interference stemming from bone metastases [20].

**Secondary endpoints**

Secondary endpoints include local tumor control, duration of pain response, toxicity, vertebral compression fractures, QOL, and overall survival. Evaluation of local tumor control will be based on imaging acquired during follow-up. Duration of pain response starts at response until pain progression or end of follow-up using information provided by the BPI. A radiation oncologist records toxicity according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0 [21] six weeks after radiation treatment. Toxicity occurring after 6 weeks, (serious) adverse events (SAEs), and hospitalization are registered in the context of the PRESENT cohort. Information about toxicity is based on clinical follow-up data and biannual patient-administered questionnaires on health status and hospitalization. All patients in the SBRT arm undergo an additional MRI scan six months after radiation in order to assess vertebral compression fractures. Since most compression fractures occur four months after radiation treatment [22], this 6-month-MRI captures most incidents. In case of clinical suspicion of a vertebral compression fracture, obtaining the MRI scan will be advanced as deemed appropriate.

**Quality of life** is measured by the EORTC QLQ-C15-PAL general questionnaire [23] and the bone metastases-specific module, the EORTC QLQ-BM22 [24]. The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC QLQ-C30 specially developed for use in palliative care. In order to evaluate the cost-effectiveness, patients are also provided with the EQ-5D questionnaire. Patients fill out these QOL questionnaires and the BPI before the start of radiation treatment (baseline) and after one, two, three, and six months, and every six months thereafter. The BPI is provided after two and six weeks as well. We make use of the digital patient tracking system PROFILES, so patients are able to complete the questionnaires online after secured login [25]. Overall survival is monitored within the PRESENT cohort by clinical follow-up and via an electronic link with the Municipal Personal Records Database.

**Safety**

We will report treatment induced SAEs within 15 days following notification through a government based internet portal to the accredited institutional review board that approved the protocol. Treatment induced SAEs that result in death or are life threatening will be reported within seven days.

**Sample size considerations**

Based on the most recent meta-analysis, we expect a pain response in 60% of patients following standard radiotherapy [3]. Pain response after stereotactic radiotherapy is assumed to be 85% [8, 9]. We expect that approximately 90% of patients who are offered SBRT treatment, will accept the offer. Cross-over from control arm to the SBRT treatment arm is extremely unlikely, since only patients who are randomly selected to receive SBRT are informed about the treatment. Taking a one-sided $\alpha$ of 5% and a power of 80%, we require 49 patients per treatment arm to show a statistically significant difference of 15% in pain response. The reason to choose a one-sided $\alpha$ is that, although improbable, inferior pain response after stereotactic treatment would lead to the same action as no difference at all between the two treatment regimens. This is because the SBRT treatment will only be implemented if it is significantly better than the usual care, since SBRT treatment is more complex, less convenient for patients, and more expensive than standard radiotherapy. Finally, to allow for a 10% drop out rate, recruitment of 55 patients per group is intended. We expect to complete recruitment within 18 months based on the number of patients we treat in our center annually.

**Data analysis**

Data will be analyzed according to the intention to treat principle. Data of eligible patients who were randomly offered stereotactic radiotherapy will be compared with eligible patients who were not randomly selected and received standard radiotherapy. In case of dropout (i.e. patients not surviving longer than three months or patients unable to provide pain scores and analgesic use), a worst-case analysis will be performed: dropped-out patients will be classified as non-responders. In case of substantial refusal of the SBRT offer in the intervention

### Table 2 Response rate to radiotherapy according to the international consensus [19]

| Responders          | Pain score of 0 and stable or reduced OMED |
|---------------------|--------------------------------------------|
| Complete response   | Pain reduction of 2 points on a 0–10 scale or more and/or OMED reduction by 25% or more |
| Partial response    | Increase of 2 points on a 0–10 scale or more above baseline, and/or OMED increased by 25% or more |
| Non-responders      | Any response including stable disease that is not captured by complete or partial response or pain progression |

OMED daily oral morphine equivalent

an increase of at least 25% in analgesic use compared to baseline with at least stable pain scores. All responses not captured with complete and partial response or pain progression are considered indeterminate response. Pain is measured by the Brief Pain Inventory (BPI), which has been validated for use in advanced cancer patients to assess pain and functional interference stemming from bone metastases [20].

---

**Table 2** Response rate to radiotherapy according to the international consensus [19]

| Responders          | Pain score of 0 and stable or reduced OMED |
|---------------------|--------------------------------------------|
| Complete response   | Pain reduction of 2 points on a 0–10 scale or more and/or OMED reduction by 25% or more |
| Partial response    | Increase of 2 points on a 0–10 scale or more above baseline, and/or OMED increased by 25% or more |
| Non-responders      | Any response including stable disease that is not captured by complete or partial response or pain progression |

OMED daily oral morphine equivalent

---

**Safety**

We will report treatment induced SAEs within 15 days following notification through a government based internet portal to the accredited institutional review board that approved the protocol. Treatment induced SAEs that result in death or are life threatening will be reported within seven days.

**Sample size considerations**

Based on the most recent meta-analysis, we expect a pain response in 60% of patients following standard radiotherapy [3]. Pain response after stereotactic radiotherapy is assumed to be 85% [8, 9]. We expect that approximately 90% of patients who are offered SBRT treatment, will accept the offer. Cross-over from control arm to the SBRT treatment arm is extremely unlikely, since only patients who are randomly selected to receive SBRT are informed about the treatment. Taking a one-sided $\alpha$ of 5% and a power of 80%, we require 49 patients per treatment arm to show a statistically significant difference of 15% in pain response. The reason to choose a one-sided $\alpha$ is that, although improbable, inferior pain response after stereotactic treatment would lead to the same action as no difference at all between the two treatment regimens. This is because the SBRT treatment will only be implemented if it is significantly better than the usual care, since SBRT treatment is more complex, less convenient for patients, and more expensive than standard radiotherapy. Finally, to allow for a 10% drop out rate, recruitment of 55 patients per group is intended. We expect to complete recruitment within 18 months based on the number of patients we treat in our center annually.

**Data analysis**

Data will be analyzed according to the intention to treat principle. Data of eligible patients who were randomly offered stereotactic radiotherapy will be compared with eligible patients who were not randomly selected and received standard radiotherapy. In case of dropout (i.e. patients not surviving longer than three months or patients unable to provide pain scores and analgesic use), a worst-case analysis will be performed: dropped-out patients will be classified as non-responders. In case of substantial refusal of the SBRT offer in the intervention
Differences with a continuous outcome over time using mixed models. We will evaluate the pattern of QOL as three months pain assessment). Differences will be tested with the χ² test. A comparison in QOL will be made between the baseline QOL and at predefined intervals after treatment. A change of 10% of the scale breadth will be considered a clinically relevant change of QOL [27]. Data will be presented as improved (≥10% increase), stable, or worsened (<10% decrease) QOL. We will evaluate the pattern of QOL as a continuous outcome over time using mixed models. Differences with a P-value <0.05 will be considered statistically significant. We have planned to perform an interim analysis after inclusion of half of the patients (i.e. 55 patients) when they have completed their follow up (i.e. three months pain assessment).

Discussion
In this report, we present the rationale and design of the VERTICAL trial. In this randomized study, we investigate whether SBRT can increase the proportion of patients with (complete or partial) pain response. Although standard radiotherapy is moderately effective in achieving pain relief in most patients with spinal metastases, up to 40% of patients do not experience any pain relief and complete response occurs in only 30% of responders [3]. Presently, it is not exactly understood why some patients do not respond adequately to standard radiotherapy. A factor that may play a role in the suboptimal response to standard radiotherapy is the way the radiation dose is delivered. Barton and colleagues [28] showed that the dose received by the vertebral column using standard radiation techniques varies by up to 50%. For instance, when using a direct posteroanterior field to deliver 8 Gy at a depth of 5 cm, metastases located in deep vertebrae receive less than 50% of the prescribed dose. This is important, since 4 Gy in one fractions is proven to be less effective than 8 Gy [29–31]. If there is indeed a threshold dose below which pain relief is less likely and of slower onset, it may be important to ensure that the vertebral metastasis receives the dose intended. However, the low tolerance of the spinal cord to radiation limits the standard radiation dose to a level that below the optimal therapeutic dose thus providing a less than optimal response. Precise confinement of the radiation dose, even including dose escalation in addition, should increase the probability of pain relief while the risk of injury to the spinal cord is minimized. Several retrospective and prospective phase II studies have indeed shown the safety and efficacy of SBRT in spinal metastases [5, 6].

Most studies on spinal SBRT included a heterogeneous patient population, including previously unirradiated patients, patients who needed reirradiation, and postoperative SBRT, and these categories include patients with or without solitary spine metastases [8, 32]. We include all unirradiated patients with spinal metastases including patients with diffuse metastases, and mild neurological complaints. In this way, we deliberately chose a pragmatic approach since we expect that this would be the patient population that is going to be treated once the benefits of SBRT would have been established. In order to investigate the effect of SBRT without the effect of additional treatments, we however exclude patients who received previous standard or stereotactic body radiotherapy or surgery to the index site. As pragmatic trials investigate the effectiveness of medical treatment strategies under usual conditions, the standard strategy (i.e. 8 Gy in a single fraction, or for selected patients 30 Gy in 10 fractions) will be compared to the SBRT strategy (which includes more dose schedules). Still, the biological effective dose (BED) of the three dose regimen is much higher compared to the BED of the conventional dose regimen. If there is a difference in pain response after SBRT compared to standard radiotherapy, we should be able to detect that differences despite the use of multiple radiation dose schedules. Traditionally, stereotactic radiotherapy in metastatic bone disease is intended for patients with spinal metastases. However, SBRT is increasing being applied in the treatment of non-spine osseous metastases [33]. Since spinal metastases are similar to non-spine osseous metastases in terms of bone involvement and pain relief after standard radiotherapy [34, 35], the response after SBRT in spinal and non-spine osseous metastases is likely to be similar as well. Therefore, we have extended the VERTICAL inclusion criteria to patients with non-spinal bony metastatic disease.

To our knowledge, six other randomized studies on spinal SBRT are currently being conducted (Table 3) [36–41]. Only two other trials require both CT and MRI imaging for the delineation of the spinal metastases [37, 38], however, these trials delineate the whole bony compartment (i.e. the CTV) that contains the metastasis instead of using an simultaneous integrated boost approach. They also have strict instructions on how to apply the standard and stereotactic body radiotherapy in contrast to our more pragmatic approach, offering radiation oncologists leeway in fractionation schedule. Furthermore, the VERTICAL trial distinguishes itself from these trials by applying the cmRCT design. The cmRCT design was proposed as a variant of classic pragmatic randomized
| Name, institution | Start date, sample size | Patients | SBRT treatment | Comparator | Primary Endpoint |
|-------------------|------------------------|----------|----------------|------------|------------------|
| Mahadevan et al. [36] Beth Israel Deaconess MC | 01–2012 81 | Number of sites not stated; Pain ≥ 5; No rapid neurologic decline | Total dose unknown in 1, 3, or 5 fractions; No more information provided | Standard EBRT in 10 fractions | Pain response<sup>b</sup> |
| RACOST [37] Radboud UMC Nijmegen | 06–2015 382 | Number of sites not stated; May have other visceral metastases; Pain ≥ 5; No rapid neurologic decline | Any modern system; 20 Gy in one fraction; Delineation with MRI and CT; Target volume is GTV, with bony CTV expansion, PTV margin ≤ 3 mm | Standard EBRT single dose of 8 Gy, no restrictions to radiation technique | Pain response taking administration of opioids into account<sup>b</sup> |
| RTOG 0631 [38] Henry Ford Hospital | 11–2011 395 | Up to 3 spinal sites; May have other visceral metastases; Pain ≥ 5; No rapid neurologic decline | IMRT or other dose painting technique; 16 or 18 Gy in one fraction; Delineation with MRI and CT; Target volume is involved VB | Standard EBRT single dose of 8 Gy, 2D and 3D conformal therapy | Pain response (increase or decrease of ≥ 3 points) at 3 months |
| SMART [39] Heidelberg University | 12–2014 60 | Up to 2 spinal sites; No neurologic deficit | IMRT; 24 Gy in one fraction; Delineation with CT; Target volume is involved VB with PTV margin | Standard EBRT 30 Gy in 10 fractions, 3D conformal planning | Pain response (increase or decrease of > 2 points) at 3 months |
| SPIN-MET [40] University of Erlangen-Nürnberg | 03–2013 155 | Number of sites not stated; May have other visceral metastases; No rapid neurologic decline | 36 Gy in 12 fractions plus integrated boost 48 Gy in 12 fractions; No more information provided | Conventional EBRT 30 Gy in 10 fractions | Tumor control defined as time to progression on MRI |
| Tingting et al. [41] Cancer Hospital of Shantou UMC | 03–2014 100 | Up to 3 spinal sites | 24 Gy in 2 fractions; No more information provided | Conventional EBRT 30 Gy in 10 fractions | Pain response taking administration of opioid into account<sup>+</sup> |
| VERTICAL University Medical Center Utrecht | 01–2015 110 | Up to 2 spinal sites; May have other visceral metastases; Pain ≥ 3; No rapid neurologic decline | VMAT; 18 Gy in one fraction or fractionated equivalent; Delineation with MRI and CT; Target volume with simultaneous integrated boost | Standard of care for standard radiotherapy | Pain response (increase or decrease of ≥ 2 points) taking administration of opioid into account at 3 months |

<sup>CT</sup> computed tomography, <sup>CTV</sup> clinical target volume, <sup>EBRT</sup> external beam radiotherapy, <sup>IMRT</sup> image guided radiotherapy, <sup>GTV</sup> gross tumor volume, <sup>MC</sup> medical center, <sup>MRI</sup> magnetic resonance imaging, <sup>PTV</sup> planning target volume, VB vertebral body

<sup>aExcluding studies on oligometastases including spinal oligometastatic disease, comparing surgery with SBRT, and studies including non-spinal lesions as well</sup>

<sup>bTime point at which endpoint is measured not given</sup>
controlled trials (RCTs) and addresses some common difficulties associated with those RCTs, such as disappointment bias, drop-outs, slow recruitment, and poor generalizability [13]. Patients and doctors often have a strong preference for the experimental treatment that has not proven to, but is expected to be superior. Investigators of the RTOG 0631 trial indeed experience that patients and their physicians prefer the SBRT treatment over standard radiotherapy [Samuel Ryu, personal communication]. Consequently, patients allocated to the standard arm may show disappointment when reporting outcomes. This is of particular concern since the primary endpoint consists of a subjective outcome (i.e. pain scores). By using the cmRCT design however, control patients are unaware of being allocated to the control arm, which will prevent disappointment bias in observed outcomes. Furthermore, standard of care is likely to be unaffected by treatment allocation and will therefore better resemble routine practice. We also expect lower drop-outs rates since patients in the control arm are not likely to withdraw from standard care, which may be of particular interest in this fragile patient population. Because of this fragility, researchers in this field should make an effort to optimize recruitment rates. The use of the cmRCT design may foster recruitment rates by its unique informed consent procedure. A reason not to take part in classic randomized studies might be that patients cannot be guaranteed to receive the desired experimental treatment. Furthermore, once participating, patients are often allowed to participate in one trial at a time only. By contrast, patients participating in a cmRCT study give broad informed consent to participate in randomized trials, but not to specific trials which may increase recruitment rates. Moreover, the cmRCT cohort offers an infrastructure which allows the conduct of randomized trials simultaneously. Finally, recruitment in cohort studies is usually more manageable compared with recruitment in RCTs. The inclusion rates in the PRESENT cohort for example are promising: the participation rate is 83%, and 88% of the participating patients have given informed consent for broad randomization to experimental interventions. The use of a cohort in cmRCT studies offers more potential advantages. Palliative patients willing to participate in randomized trials often represent a relatively healthier and higher-educated subgroup. By using a cohort as a recruitment pool for RCTs, a more routine population is included since recruitment for cohort studies is generally less selective. Moreover, the cohort provides information on baseline characteristics and outcome measurements (i.e. the regular cohort measures) of drop-outs, which is essential in the data analysis. Patients allocated to the control arm, are cohort participants who receive the current standard of care (i.e. standard radiotherapy in the PRESENT case). In our department, the standard of care for patients with bone metastases will change from standard radiotherapy to automatically generated conformal treatment plans. Would the VERTICAL trial have been conventionally conducted, this could have been problematic since control patients in the VERTIcal trial would then have been withhold from standard of care. However, the cmRCT design has the advantage that experimental interventions are compared with the most up-to-date standard of care, instead of competing with outdated treatments, which is often the case in completed classic RCTs. Finally, a valuable feature of the cmRCT design is the opportunity to evaluate and quantify the acceptance rates of the offered treatment (i.e. SBRT). This offers new insights into patient preferences and reasons for refusal of SBRT. We feel that prevention of disappointment bias, more efficient and less selective patient recruitment, up-to-date standard of care, and quantifying patients’ preference could significantly improve trials conducted according to the cmRCT design.

In conclusion, the VERTIcal study is a pragmatic randomized trial, following the cmRCT design, which compares stereotactic radiotherapy with standard radiotherapy in patients with spinal metastases in terms of pain response, with the ultimate goal to improve quality of life.

**Abbreviations**
BED: Biological effective dose; BPI: Brief pain inventory; CBCT: Cone beam computed tomography; cmRCT: Cohort multiple randomized controlled trial design; CT: Computed tomography; CTV: Clinical tumor volume; EORTC: European organization for research and treatment of cancer; GTV: Gross tumor volume; Gy: Gray; IMRT: Intensity-modulated radiation therapy; KPS: Karnofsky performance score; MRI: Magnetic resonance imaging; MV: Megavoltage; OAR: Organs at risk; PRESENT: Prospective evaluation of interventional Studies on bone meTastases cohort; PROFILES: Patient reported outcomes following initial treatment and long term evaluation of survivorship; PROMs: Patient-reported outcomes; QoL: Quality of life; RCT: Randomized controlled trial; SAE: Serious adverse event; SBRT: Stereotactic body radiotherapy; VERTIcal: Comparison of conVeNTional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases; VMAT: Volumetric modulated arc therapy

**Acknowledgements**
The authors wish to thank dr. Arjun Sahgal for his valuable advice in the concept and design of the VERTIcal trial.

**Funding**
Not applicable.

**Availability of data and materials**
Not applicable – data collection is still ongoing.

**Authors’ contributions**
MvdV participated in design of the study, coordinated study procedures and drafted the manuscript. HV particpated in design of the study, and revised the manuscript critically. ES and JH designed the technical treatment strategy and calculated treatment plan parameters. ASG coordinated study procedures, and revised the manuscript critically. WSCE, NK and JHV helped design the study. MvV participated in the study design and coordination and revised the manuscript critically. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Institutional review board approval was obtained separately for both the PRESENT cohort (particularly the cmfRCT infrastructure) and the VERTICAL study from the ethical committee of the University Medical Center Utrecht (reference numbers 13-261 and 14-275, respectively). The PRESENT cohort is published under NCT02356497 and the VERTICAL study under NCT02364115 on ClinicalTrials.gov. Written informed consent is obtained from all participants.

Trial status
The study protocol was approved by the institutional review board in November 2014. Recruitment started in January 2015 and is currently ongoing.

Author details
1Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. 2Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 3Department of Orthopedic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Received: 29 September 2015 Accepted: 10 November 2016

Published online: 21 November 2016

References
1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:2643–59.
2. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79:965–76.
3. Chow E, Zeng L, Salvo N, Dennisk T, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol. 2012;24:112–24.
4. Huisman M, van den Bosch MA, Wijlemans JN, van Vulpen M, van der Linden YM, Verkooijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2012;84:8–14.
5. Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys. 2008;71:652–65.
6. Bhattacharya IS, Hoskin PJ. Stereotactic body radiotherapy for spinal and bone metastases. Clin Oncol. 2015;27:298–306.
7. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gining I, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 2012;13:395–402.
8. Gierszen PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine. 2007;32:193–9.
9. Ryu S, Jin R, Jin JY, Chen Q, Rock J, Anderson J, et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manage. 2008;35:292–8.
10. Lee S, Chun M. Pain relief by cyberknife radiosurgery for spinal metastasis. Tumori. 2012;98:238–42.
11. Moher D, Schulz KF, Altman DG. CONSORT. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001;1:12.
12. Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort. ClinicalTrials.gov NCT02356497. https://clinicaltrials.gov/show/NCT02356497. Accessed 01 Jul 2015.
13. Retlon C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMC. 2010;340:1066.
14. Young-Afat DA, Verkooijen HM, van Gils CH, Elias SG, Van der Velden JM, Burbach JPM, et al. Staged-informed consent in the cohort multiple randomized controlled trial design: rethinking patient-centered informed consent to avoid pre-randomization. Epidemiology. 2016;27:389–92.
15. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53.
16. Sohn MJ, Lee DJ, Yoon SW, Lee HR, Hwang YJ. The effective application of segmental image fusion in spinal radiosurgery for improved targeting of spinal tumours. Acta Neurochir. 2009;151:231–8. Discussion 238.
17. Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, et al. Phase III trial of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007;7:151–60.
18. Kuiper IT, Dahele M, Senan S, Verbakel WF. Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: a planning study and early clinical data. Radiother Oncol. 2010;94:224–8.
19. Chow E, Hoskin P, Miteva G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82:1730–7.
20. Wu JS, Beaton D, Smith PM, Hagen NA. Patterns of pain and interference in patients with painful bone metastases: a brief pain inventory validation study. J Pain Symptom Manage. 2010;39:230–40.
21. National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) v4 data files. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 01 Jul 2015.
22. Sahgal A, Atenafu EG, Chao S, Al-Omair A, Boeijing N, Balagamwala EH, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013;31:3426–31.
23. Groenewold M, Petersen MA, Aaronsen NK, Anras J, Blazevy JM, Bottomley A, EORTC Quality of Life Group, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42:55–64.
24. Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, et al. Quality of life after palliative radiotherapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BMV2. Int J Radiat Oncol Biol Phys. 2012;84:e337–42.
25. Van de Poll-Franse LV, Horevoorts N, van Eemeren M, Denollet J, Roukema JA, Aaronsen NK, Profiles Registry Group, et al. The patient reported outcomes following initial treatment and long term evaluation of surwvivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47:2188–94.
26. Sussman JB, Haywood RA. An IV for the RCT: using instrumental variables to adjust for intervention contamination in randomised controlled trials. BMJ. 2010;340:c2073.
27. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the national cancer institute of canada clinical trials group. Eur J Cancer. 2005;41:280–87.
28. Barton R, Robinson G, Gutierrez E, Kirkbride P, McLean M. Palliative radiation for vertebral metastases: the effect of variation in prescription parameters on the dose received at depth. Int J Radiat Oncol Biol Phys. 2002;53:1083–91.
29. Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23:74–8.
30. Jerome B, Shibamoto Y, Acinovic L, Millicic B, Miklavjemic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Radiother Oncol. 1998;42:161–7.
31. Hoskin P, Rojas A, Fidarova E, Jalali R, Mena Merino A, Poietvin A, et al. IAEA randomized trial of optimal single dose radiotherapy in the treatment of painful bone metastases. Radiother Oncol. 2015;116:10–4.
32. Guckenberger M, Mantel F, Gersten PC, Flickinger JC, Sahgal A, Létourneau D, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiother Oncol. 2014;92:226.
33. Lewis SL, Porceddu S, Nakamura N, Palma DA, Lo SS, Hoskin P, et al. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol. 2015;38:494–500. [Epub ahead of print].
34. Hartsell WF, Scott CB, Bruner DW, Scastiantino CW, Iker RA, Roach 3rd M, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798–804.
35. Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, et al. Single-fraction radiotherapy versus multifraction radiotherapy for...
palliation of painful vertebral bone metastases—equivalent efficacy, less
toxicity, more convenient: a subset analysis of radiation therapy oncology
group trial 97–14. Cancer. 2013;119:888–96.
36. Randomized Study of Stereotactic Body Radiotherapy vs. Conventional
Radiation for Spine Metastasis. ClinicalTrials.gov NCT01525745. https://
clinicaltrials.gov/show/NCT01525745. Accessed 07 Jul 2015.
37. Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality
of Life in Spinal Metastases (RACOST). ClinicalTrials.gov NCT02407795.
https://clinicaltrials.gov/show/NCT02407795. Accessed 07 Jul 2015.
38. Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in
Treating Patients With Localized Spine Metastasis. ClinicalTrials.gov
NCT00922974. https://clinicaltrials.gov/show/NCT00922974. Accessed 07 Jul 2015.
39. Rief H, Katayama S, Bruckner T, Rieken S, Bostel T, Förster R, et al. High-dose
single-fraction IMRT versus fractionated external beam radiotherapy for
patients with spinal bone metastases: study protocol for a randomized
controlled trial. Trials. 2015;16:264.
40. Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by
Hypofractionated Radiation and IGRT hSRT Mediated Boost (SPIN-MET).
ClinicalTrials.gov NCT01849510. https://clinicaltrials.gov/ct2/show/
NCT01849510. Accessed 07 Jul 2015.
41. Randomized phase II/III trial of stereotactic body radiotherapy versus
conventional multi-fractional radiotherapy for spine metastases. Chinese
Clinical Trial Registry ChiCTR-TRC-14004281. http://www.chictr.org.cn/
showprojen.aspx?proj=5287. Accessed 07 Jul 2015.